Prostate | Urinary Bladder, Phase I-II
An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
Volunteers
Health Professionals
What is the purpose of this trial?
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Caitlin Gallagher
- Clarice Grens
- Curtis Jamison Perry, MD, PhD
- Emily Kopas, APRN, OCN
- Harold Tara Jr, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Joseph Kim, MD
- Larisa Fleysher
- Lynn Mastrianni
- Megan Shulman
- Michael Cecchini, MD
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Raghav Sundar, MD, PhD
- Robert Legare, MD
- Robert Matera, MD
- Stephen Lattanzi, MD
- Teresa White
- Thejal Srikumar, MD, MPH
- Vanna Dest
- William K. Oh, MD
- Yifei Zhang, MD
- Last Updated10/30/2025
- Study HIC#2000039989